HK1048593A1 - 用於通過體內基因輸送治療心血管疾病的技術和組合物 - Google Patents

用於通過體內基因輸送治療心血管疾病的技術和組合物

Info

Publication number
HK1048593A1
HK1048593A1 HK03100751.6A HK03100751A HK1048593A1 HK 1048593 A1 HK1048593 A1 HK 1048593A1 HK 03100751 A HK03100751 A HK 03100751A HK 1048593 A1 HK1048593 A1 HK 1048593A1
Authority
HK
Hong Kong
Prior art keywords
vivo
compositions
techniques
cardiovascular disease
gene delivery
Prior art date
Application number
HK03100751.6A
Other languages
English (en)
Inventor
Kirk Hammond H
J Giordano Frank
H Dillmann Wolfgang
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of HK1048593A1 publication Critical patent/HK1048593A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK03100751.6A 1999-11-05 2003-01-29 用於通過體內基因輸送治療心血管疾病的技術和組合物 HK1048593A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43515699A 1999-11-05 1999-11-05
US60908000A 2000-06-30 2000-06-30
PCT/US2000/030345 WO2001034208A1 (en) 1999-11-05 2000-11-03 Techniques and compositions for treating cardiovascular disease by in vivo gene delivery

Publications (1)

Publication Number Publication Date
HK1048593A1 true HK1048593A1 (zh) 2003-04-11

Family

ID=27030448

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03100751.6A HK1048593A1 (zh) 1999-11-05 2003-01-29 用於通過體內基因輸送治療心血管疾病的技術和組合物

Country Status (10)

Country Link
EP (1) EP1225921A1 (zh)
JP (1) JP2003513942A (zh)
KR (1) KR20020049031A (zh)
CN (1) CN1433325A (zh)
AU (1) AU784392B2 (zh)
CA (1) CA2389524A1 (zh)
EA (1) EA008538B1 (zh)
HK (1) HK1048593A1 (zh)
NZ (1) NZ546670A (zh)
WO (1) WO2001034208A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1433325A (zh) * 1999-11-05 2003-07-30 加利福尼亚大学董事会 通过体内基因递送治疗心血管疾病的技术和组合物
US20030093147A1 (en) * 2001-11-13 2003-05-15 Ogle Matthew F. Medical devices that stimulate growth factor production
KR100562824B1 (ko) 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
PL195457B1 (pl) * 2002-08-05 2007-09-28 Zaklady Farm Polpharma Sa Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie
CA2658628A1 (en) * 2006-07-25 2008-01-31 Celladon Corporation Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy
PL2197900T3 (pl) * 2007-08-24 2012-12-31 Univ Wuerzburg J Maximilians Zmutowane podwójnie cyklizowane peptydy receptorowe hamujące przeciwciała przeciwko beta 1-adrenoreceptorowi
BRPI0911511B8 (pt) 2008-04-09 2021-05-25 Helixmith Co Ltd formulação de dna liofilizadas para aumentar a expressão de dna de plasmídeo
WO2010078624A1 (en) * 2009-01-07 2010-07-15 Vegenics Limited Materials and methods for the treatment of hypertension
KR101006106B1 (ko) * 2009-06-04 2011-01-07 김현태 전·자기장 차단 전열선
US10155099B2 (en) 2009-09-21 2018-12-18 Cook Regentec Llc Method for infusing stem cells
HUE036640T2 (hu) * 2012-02-14 2018-07-30 Univ California Parakrin gének szisztémás bejuttatása és szabályozott expressziója szív és érrendszeri betegségekre és egyéb állapotokra
KR20150016970A (ko) 2012-06-05 2015-02-13 머핀 인코포레이티드 세포 치료요법에 유용한 카테터 시스템 및 방법
BR112016008267A2 (pt) 2013-10-22 2017-10-03 Viromed Co Ltd Composição para prevenir ou tratar esclerose lateral amiotrófica usando duas ou mais isoformas de fator de crescimento de hepatócito
US20210393805A1 (en) * 2018-05-16 2021-12-23 University Of Massachusetts Perfusion-based delivery of recombinant aav vectors for expression of secreted proteins
AU2019305221A1 (en) 2018-07-19 2021-02-18 Helixmith Co., Ltd. Lyophilized pharmaceutical compositions for naked DNA gene therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1136920C (zh) * 1995-02-28 2004-02-04 加利福尼亚大学董事会 基因转移介导的血管形成疗法
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
AU745409B2 (en) * 1997-01-29 2002-03-21 Cornell Research Foundation Inc. Multiple site delivery of adenoviral vector for the induction of angiogenesis
KR20070005030A (ko) * 1997-05-06 2007-01-09 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 혈관형성성 트랜스유전자의 생체내 송달에 의한 심장 질환및 심실 리모델링을 치료하기 위한 방법 및 조성물
CN101186928A (zh) * 1998-02-11 2008-05-28 加利福尼亚大学董事会 核酸和血管活性剂相组合用于加强的基因投递
AU763049B2 (en) * 1998-12-28 2003-07-10 Arch Development Corporation Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinantadeno-associated virus vectors
CN1433325A (zh) * 1999-11-05 2003-07-30 加利福尼亚大学董事会 通过体内基因递送治疗心血管疾病的技术和组合物

Also Published As

Publication number Publication date
AU784392B2 (en) 2006-03-23
AU1460401A (en) 2001-06-06
EP1225921A1 (en) 2002-07-31
EA008538B1 (ru) 2007-06-29
WO2001034208A1 (en) 2001-05-17
NZ546670A (en) 2009-02-28
JP2003513942A (ja) 2003-04-15
CA2389524A1 (en) 2001-05-17
EA200200533A1 (ru) 2002-12-26
CN1433325A (zh) 2003-07-30
KR20020049031A (ko) 2002-06-24

Similar Documents

Publication Publication Date Title
AU2002305346A1 (en) Techniques and compositions for treating cardiovascular disease by (in vivo) gene delivery
AU3692001A (en) Compositions and methods for enhancing drug delivery across biological membranesand tissues
HK1048593A1 (zh) 用於通過體內基因輸送治療心血管疾病的技術和組合物
EP1152764A4 (en) COMPOSITIONS AND METHODS OF USE IN THE OBJECTIVE OF VASCULAR DESTRUCTION
HK1039571A1 (en) Compositions and methods for mucosal delivery
MXPA03007590A (es) Composiciones y metodos para mejorar suministro de droga a traves de y dentro de tejidos oculares.
PL338846A1 (en) Starch compositions suitable for treatment in molten state
HUP0200409A3 (en) Valdecoxib compositions, process for their preparation and their use
EP1165586A4 (en) TCL-1B GENES AND PROTEINS AND RELATED METHODS AND METHODS
HUP0203590A3 (en) Remedies for diseases in association with decrease in bone mass
HUP0200275A3 (en) Seed treatment composition and preparation thereof
EP1180006A4 (en) COMPOSITIONS AND METHODS FOR PREPARING SUCH COMPOSITIONS FROM LEPIDIA
EP1470240A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES USING 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419 , 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2
MXPA02003232A (es) Composiciones y metodos para alternar la expresion de genes.
EP1583966A4 (en) METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASES USING GENES 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33
EP1233671A4 (en) COMPOSITIONS AND METHODS OF DISPOSING MEDICAMENTS USING AMPHIPHILIC BINDING MOLECULARS
EP1311192A4 (en) -G- (IN VIVO) IMAGING
IL148946A0 (en) Altering gene expression with ssdna produced in vivo
AU2002306461A1 (en) In vivo delivery methods and compositions
ZA200203435B (en) Method and compositions for treating pulmonary diseases.
EP1173192A4 (en) METHOD AND COMPOSITIONS FOR TARGETED MEDICINE ADMINISTRATION
IL149451A0 (en) Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
ZA200203303B (en) Techniques and compositions for treating cardiovascular disease by in vivo gene delivery.
AU2002226986A1 (en) In vivo delivery methods and compositions
HU0103686D0 (en) Pharmaceutical composition for preventing or treating diseases associated with an excess in il-12 production